test - SGLT2 inhibitor benefits younger, overweight, poorly controlled T2DM patients
SGLT2 inhibitor benefits younger, overweight, poorly controlled T2DM patients
Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials
Literature - Romera I et al., J Diabetes Complications. 2016 - J Diabetes Complications. 2016; published online ahead of printBackground
The percentage of overweight individuals under 65 with type 2 diabetes mellitus (T2DM) and poor blood glucose control is rising. The combination of poor blood glucose control, BMI > 25 kg/m2 and younger age, exposes these individuals to increased hyperglycaemic states and a higher risk of long-term complications [1,2].
Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit renal glucose reabsorption and minimise excess glucose in the urine, leading to significant HbA1c reductions particularly in overweight/obese patients [3]. Empagliflozin, a SGLT2 inhibitor, is also associated with body weight and systolic blood pressure reductions [4].
In this analysis from three phase 3 studies, the efficacy and safety of empagliflozin was evaluated in 439 T2DM patients younger than 65 years, with BMI 25–35 kg/m2 and poorly controlled HbA1c (≥64 mmol/mol), despite diet, exercise and a stable regimen (>12 weeks) of anti-diabetes treatment.
Main results
- Adjusted mean change in HbA1c levels from baseline to week 24 of treatment with empagliflozin 10mg vs. placebo was −0.91% (95%CI: −1.11 to −0.71; P < 0.001) and with empagliflozin 25mg vs. placebo was −0.91% (95%CI: −1.12 to −0.70; P < 0.001).
- The percentage of participants with baseline HbA1c ≥ 64 mmol/mol (8%) achieving a value < 53 mmol/mol (7%) at 24 week was 23.8% vs. 3.6% for empagliflozin 10mg vs. placebo (OR: 8.69; 95% CI: 3.23-23.47; P<0.001) and 19.9% vs. 3.6% for empagliflozin 25mg vs. placebo (OR: 7.65; 95% CI: 2.77-21.11; P<0.001).
Adjusted mean change from baseline in body weight reduction at week 24 was −1.61 kg (95%CI: −2.16 to −1.05; P<0.001) for empagliflozin 10mg vs. placebo, and −1.81 kg (95% CI: −2.38 to −1.24; P<0.001) for empagliflozin 25mg vs. placebo.
- No statistically significant differences were seen between empagliflozin and placebo in changes in blood pressure at 24 weeks, with the exception of a lower diastolic blood pressure seen with empagliflozin 25mg vs. placebo (-2.0 mmHg, 95%CI: -3.6 to -0.4, P=0.015).
- Empagliflozin was well tolerated. Overall, adverse effects (AEs) were distributed similarly across treatment groups, except for a higher percentage of confirmed hypoglycaemia AEs with empagliflozin (5.6% and 5.0% for 10 and 25 mg respectively, vs. 3.6% with placebo) and genital infections (3.8% and 5.0% vs 1.4% with placebo).
Conclusion
In T2DM patients younger than 65 years, with BMI 25–35 kg/m2 and poorly controlled HbA1c levels (≥64 mmol/mol), the addition of empagliflozin to oral standard therapies was associated with a clinically and statistically significant reduction in HbA1c and in body weight compared to placebo, with a favourable safety profile. These data support an added benefit of the use of empagliflozin on top of standard therapy in this patient group.
Share this page with your colleagues and friends: